Denali Therapeutics Total Assets 2016-2024 | DNLI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Denali Therapeutics total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Denali Therapeutics total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$127.1B
Gilead Sciences (GILD)	$114.2B
Bristol Myers Squibb (BMY)	$112.1B
CSL (CSLLY)	$91B
Regeneron Pharmaceuticals (REGN)	$89.7B
GSK (GSK)	$74.4B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Biogen (BIIB)	$25.4B
BioNTech SE (BNTX)	$25.4B
Illumina (ILMN)	$24.2B
Moderna (MRNA)	$19.9B
BeiGene (BGNE)	$19.7B
Incyte (INCY)	$15.6B
Genmab (GMAB)	$14.8B
Insmed (INSM)	$13B
Vaxcyte (PCVX)	$13B
BioMarin Pharmaceutical (BMRN)	$12.6B
Sarepta Therapeutics (SRPT)	$12.2B
Bio-Techne Corp (TECH)	$12B
Exelixis (EXEL)	$10.1B
Exact Sciences (EXAS)	$10.1B
QIAGEN (QGEN)	$10B
Revolution Medicines (RVMD)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.2B
Ascendis Pharma (ASND)	$7.8B